Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Afya
AFYA
Market cap
$1.35B
Overview
Fund Trends
Analyst Outlook
Journalist POV
14.90
USD
+0.13
0.88%
At close
Updated
Oct 17, 4:00 PM EDT
Pre-market
After hours
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
0.88%
5 days
2.97%
1 month
-6.52%
3 months
-1.59%
6 months
-18.13%
Year to date
-4.67%
1 year
-10.3%
5 years
-40.11%
10 years
-38.15%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
33.3%
Negative
Positive
Neutral
Negative
Neutral
Business Wire
9 days ago
Issuance of Debentures
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that its wholly owned subsidiary Afya Participações S.A. (“Afya Brazil”), has approved today the first issuance of book-entry commercial notes, in two series, for private placement, (the “Commercial Notes”), to be sold to Opea Securitizadora S.A. (“Opea”), a Brazilian securitization corp.
Positive
Seeking Alpha
2 months ago
Afya's Multiple Is Back To Reasonable Levels, But Market Saturation Is Real
Afya's Q2 2025 results were solid, but the stock faces headwinds from market saturation and regulatory changes in Brazil's medical education sector. Valuation is now more attractive after a 20%+ price drop, but risks from lower pricing power, increased competition, and new quality exams remain significant. The company is shifting capital allocation toward buybacks and dividends, signaling fewer expansion opportunities and a focus on shareholder returns.
Neutral
Seeking Alpha
2 months ago
Afya Limited (AFYA) Q2 2025 Earnings Call Transcript
Afya Limited (NASDAQ:AFYA ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Luis Andre Carpintero Blanco - Chief Financial Officer Virgilio Deloy Capobianco Gibbon - Chief Executive Officer Conference Call Participants Flavio Yoshida - BofA Securities, Research Division Lucca Generali Marquezini - Itaú Corretora de Valores S.A., Research Division Marcelo Peev dos Santos - JPMorgan Chase & Co, Research Division Mauricio I Cepeda - Morgan Stanley, Research Division Renan Prata - Citigroup Inc. Exchange Research Samuel Campos Alves - Banco BTG Pactual S.A.
Neutral
Business Wire
2 months ago
Afya Limited Announces Second-Quarter and First-Half 2025 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highligh.
Neutral
Business Wire
2 months ago
Afya Limited Announces a New Share Repurchase Program
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning.
Positive
Zacks Investment Research
2 months ago
Best Growth Stocks to Buy for August 6th
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today August 6th:
Positive
Zacks Investment Research
2 months ago
Best Growth Stocks to Buy for August 4th
PRIM, AFYA and JBL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 4, 2025.
Positive
Zacks Investment Research
2 months ago
Best Growth Stocks to Buy for July 31st
AFYA, ROAD and PAAS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 31, 2025.
Positive
Zacks Investment Research
2 months ago
Best Growth Stocks to Buy for July 29th
AFYA, ROAD and PAAS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 29, 2025.
Positive
Zacks Investment Research
2 months ago
AFYA vs. LOPE: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Schools sector might want to consider either Afya (AFYA) or Grand Canyon Education (LOPE). But which of these two stocks is more attractive to value investors?
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close